ResMed Q4 Earnings Call Highlights

ResMed (RMD) reported Q4 FY2026 revenue growth of 9% y/y (8% constant currency) driven by higher demand for sleep devices and masks. Non-GAAP EPS rose 16% to $2.95, and gross margin expanded despite ongoing inflationary pressure in electronic components and freight.

Analysis

The key signal is not the top-line print itself, but that margin expanded despite input inflation. That implies ResMed is still getting either price/mix leverage or manufacturing efficiency gains, which matters because its business has a recurring consumables component that compounds faster than the installed base cycle. In healthcare hardware, that usually translates into earnings durability rather than a one-quarter pop, and it supports a premium multiple if growth stays in the high-single digits.

Competitive dynamics remain favorable for RMD versus the broader sleep-apnea ecosystem. Any share recapture from rivals will show up first in masks and replacement accessories, then in device placements; that means the more durable upside is in recurring consumables, while the device line is the leading indicator. The second-order loser is any competitor still relying on recall remediation or slower distribution recovery, because RMD’s margin strength suggests it can spend into channels without sacrificing profitability.

The main risk is that this is a quality-inflation story the market already knows, so upside may be capped unless management raises guidance or shows accelerating device demand. Over 1-3 months, the stock is likely to trade with conviction on whether gross margin can stay elevated into the next quarter; over 6-18 months, the thesis breaks if reimbursement pressure, distributor destocking, or slowing CPAP patient starts reduces replacement cadence. Falsifier: any guide implying revenue growth falls back into low-single digits or gross margin rolls over despite stable volumes.

Key Decisions for Investors

• Buy RMD on any 3-5% post-earnings pullback; target a 6-12 month hold, with the thesis invalidated if next-quarter gross margin guidance gives back more than ~100 bps or revenue growth slips below 6%.
• Pair trade: long RMD / short PHG on a 1-3 month horizon to express continued share reallocation in sleep therapy; this works best if RMD keeps expanding margin while Philips remains in slower recovery mode.
• If already long, sell downside puts rather than chase upside calls; the setup favors owning quality on pullbacks because the immediate catalyst is mainly guidance durability, not a step-function acceleration.
• Watch for mask/accessory channel data over the next 1-2 quarters; if replacement growth is the real driver, that supports a longer-duration bull case, while a device-only mix shift would argue for taking profits.